PULMHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 14 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Pulmatrix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PULM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 15 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Apr 2021 | HC Wainwright & Co. | Maintains | Buy | $10 → $5.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PULM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Sept 2026, Pulmatrix, Inc. returned −72.2% against +15.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 30% of US stocks
Cheaper than 66% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 14% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pulmatrix, Inc. has a market value of $5.3M and an enterprise value of $4.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$4.0M.
Free cash flow in the twelve months to 30 June 2026: −$3.9M.
Trailing P/E: −1.0×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Pulmatrix, Inc. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pulmatrix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pulmatrix announced its second quarter 2026 financial results and provided a corporate update on its merger agreement with Eos SENOLYTIX. A Form S-4 related to the announced merger was filed.
Why it matters — PULM watchers would care because the filing and update signal progress in the company's announced merger with Eos SENOLYTIX alongside its quarterly results.
Of the 1 analysts covering Pulmatrix, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmatrix, Inc. 43 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Sept 2026, Pulmatrix, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
No analyst covering Pulmatrix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PULM are extrapolating price history, which says nothing about the business.
Pulmatrix, Inc. returned -72.2% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine.
The most recent item we track (PRNewsWire, 13 Aug 2026): "Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger". Pulmatrix announced its second quarter 2026 financial results and provided a corporate update on its merger agreement with Eos SENOLYTIX. A Form S-4 related to the announced merger was filed.
Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine. The company’s work centers on its proprietary iSPERSE engineered dry powder delivery platform, which is designed to deliver small and large molecule drugs directly to the lungs for local or systemic use. Pulmatrix’s current product candidates address serious conditions with unmet medical needs, including chronic obstructive pulmonary disease, allergic bronchopulmonary aspergillosis, and acute migraine. Its research and development activity is concentrated on creating inhaled formulations that may improve drug delivery efficiency and patient tolerability. Based in Framingham, Massachusetts, Pulmatrix operates within the biotechnology and pharmaceutical sectors, where it contributes to the development of specialized pulmonary-delivered therapeutics.
CEO Mr. Peter Ludlum CMA, MBA · 2 employees · United States · https://www.pulmatrix.com
